Ionis Pharmaceuticals (IONS) Gets a Buy from Bank of America Securities
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $97.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gerberry covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Alkermes, and Ionis Pharmaceuticals. According to TipRanks, Gerberry has an average return of 15.2% and a 60.49% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ionis Pharmaceuticals with a $90.29 average price target.
Based on Ionis Pharmaceuticals’ latest earnings release for the quarter ending October 28, the company reported a quarterly revenue of $156.72 million and a GAAP net loss of $128.61 million. In comparison, last year the company earned a revenue of $133.81 million and had a GAAP net loss of $140.48 million
Based on the recent corporate insider activity of 126 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IONS in relation to earlier this year. Most recently, in November 2025, Joan Herman, a Director at IONS sold 44,000.00 shares for a total of $3,173,720.00.
Read More on IONS:
Disclaimer & DisclosureReport an Issue
- Ionis Pharmaceuticals price target raised to $100 from $82 at Wells Fargo
- Cathie Wood Wraps Up 2025 with New Biotech Buys — Here’s What It Sold
- Cathie Wood Closes Out 2025 with a Rocket Lab (RKLB) Trim and Fresh Biotech Bets
- IONS, IBTA, IRDM: Cathie Wood Continues Trimming Stakes in Ionis, Ibotta, and Iridium Stocks
- Ionis Pharmaceuticals price target raised to $95 from $82 at RBC Capital
